Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

788
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
788
Positron Emission Tomography01:29

Positron Emission Tomography

8.1K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
8.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Concurrent Evaluation of Liver and Kidney Function by NIR-II <i>In Vivo</i> Imaging to Assess the Efficacy of Flavonoids in Preventing Their Injuries.

Chemical & biomedical imaging·2026
Same author

Novel 1‑Phenyl-2,3-dihydroquinazolin-4(1H)-one Derivatives as Na<sub>v</sub> 1.8 Voltage-Gated Sodium Channels Inhibitors.

ACS medicinal chemistry letters·2026
Same author

Novel Pyrido[4,3‑<i>d</i>]pyrimidine Derivatives as Kirsten Rat Sarcoma (KRAS) G12C Potential Inhibitors.

ACS medicinal chemistry letters·2026
Same author

Novel Macrocyclic Compounds Targeting STING for Autoimmune Diseases Treatment.

ACS medicinal chemistry letters·2026
Same author

Novel Substituted Tetrahydropyrrolooxazolones as RIPK1 Inhibitors.

ACS medicinal chemistry letters·2026
Same author

Discovery of Novel Benzothiazole-Based PDE4 Inhibitors for Central Nervous System Disorders.

ACS medicinal chemistry letters·2026
Same journal

Semisynthesis of Mycothiazole Analogs having Distinct Bioactivity.

ACS medicinal chemistry letters·2026
Same journal

Investigation on the Cytotoxicity of Hydroxycinnamic and Hydroxybenzoic Acid-Based Natural Antioxidant Conjugated Terpyridine Analogues toward Triple-Negative Breast Cancer.

ACS medicinal chemistry letters·2026
Same journal

Beyond Neddylation Inhibition: X‑ray Structures Reveal Carbonic Anhydrase Isoform Selectivity of Pevonedistat.

ACS medicinal chemistry letters·2026
Same journal

Structure-Guided Discovery of Selective Polo-Like Kinase 3 Inhibitors.

ACS medicinal chemistry letters·2026
Same journal

Controlling Neuroplasticity Across Scales: Constrained Serotonergic Agonists, Neuroplastogens, and Adaptive Neuromodulation.

ACS medicinal chemistry letters·2026
Same journal

Degradation and Detection: Integrating BCL6 Targeted Protein Degradation with Biomarker-Guided BET Inhibition in Cancer.

ACS medicinal chemistry letters·2026
See all related articles

Related Experiment Video

Updated: Apr 16, 2026

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
10:47

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

9.5K

GHSR-Targeted PET Imaging Probe.

Ruihu Song1, Steven H Liang1,2

  • 1Department of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia 30322, United States.

ACS Medicinal Chemistry Letters
|April 15, 2026
PubMed
Summary
This summary is machine-generated.

A new PET tracer, [18F]-AQ-12, shows promise for imaging the growth hormone secretagogue receptor (GHSR). It exhibits high pancreatic uptake, aiding disease diagnosis and GHSR research.

Keywords:
Ghrelin receptor (GHSR)PETdiabetesfluorine 18myocarditispancreas

More Related Videos

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

2.1K
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.7K

Related Experiment Videos

Last Updated: Apr 16, 2026

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
10:47

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

9.5K
Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

2.1K
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.7K

Area of Science:

  • Biomedical imaging
  • Molecular imaging
  • Radiochemistry

Background:

  • The growth hormone secretagogue receptor (GHSR) is a key molecular target found in various tissues, including the brain, peripheral organs, and tumors.
  • GHSR plays a crucial role in physiological and pathological processes, making it significant for both research and clinical applications.
  • Existing positron emission tomography (PET) probes for GHSR have limitations, driving the need for improved imaging agents.

Purpose of the Study:

  • To evaluate the potential of a novel PET tracer, [18F]-AQ-12, for imaging GHSR expression.
  • To assess the pharmacokinetic and binding properties of [18F]-AQ-12 in GHSR-expressing tissues.
  • To provide insights for optimizing GHSR-targeted ligands and drug development.

Main Methods:

  • Development and characterization of the novel PET tracer [18F]-AQ-12.
  • In vitro and in vivo evaluation of tracer properties, including lipophilicity and binding affinity.
  • Assessment of pancreatic uptake in GHSR-expressing tissues using PET imaging.
  • Structure-activity relationship (SAR) analysis of [18F]-AQ-12 and related compounds.

Main Results:

  • [18F]-AQ-12 demonstrated favorable low lipophilicity.
  • The tracer exhibited comparable binding affinity to existing GHSR ligands.
  • Notably higher uptake of [18F]-AQ-12 was observed in GHSR-expressing pancreatic tissue.
  • Systematic SAR analyses provided a clear understanding of the compound's structure-activity relationships.

Conclusions:

  • [18F]-AQ-12 is a promising PET tracer for visualizing GHSR.
  • Its favorable properties and high pancreatic uptake offer advantages for disease diagnosis and mechanistic studies.
  • The delineated SAR data will guide the development of next-generation GHSR-targeted imaging agents and therapeutics.